Home / ICD-10-CM / Chapter 20 / T44

T44 Drugs primarily affecting the autonomic nervous system

ICD-10-CM category T44 sits in Chapter 20 (External causes of morbidity, V00-Y99). It contains 198 billable codes for FY2027, effective October 1, 2026 to September 30, 2027. Always code to the most specific code available: a code with more characters that describes the diagnosis more precisely takes priority over a shorter one.

Subcategories

T44.0 Anticholinesterase agentsT44.0X Anticholinesterase agentsT44.0X1 Poisoning by anticholin agents, accidental (unintentional)T44.0X2 Poisoning by anticholinesterase agents, self-harmT44.0X3 Poisoning by anticholinesterase agents, assaultT44.0X4 Poisoning by anticholinesterase agents, undeterminedT44.0X5 Adverse effect of anticholinesterase agentsT44.0X6 Underdosing of anticholinesterase agentsT44.1 ParasympathomimeticsT44.1X ParasympathomimeticsT44.1X1 Poisoning by oth parasympath, accidental (unintentional)T44.1X2 Poisoning by oth parasympathomimetics, intentional self-harmT44.1X3 Poisoning by other parasympathomimetics, assaultT44.1X4 Poisoning by other parasympathomimetics, undeterminedT44.1X5 Adverse effect of other parasympathomimetics [cholinergics]T44.1X6 Underdosing of other parasympathomimetics [cholinergics]T44.2 Ganglionic blocking drugsT44.2X Ganglionic blocking drugsT44.2X1 Poisoning by ganglionic blocking drugs, accidentalT44.2X2 Poisoning by ganglionic blocking drugs, self-harmT44.2X3 Poisoning by ganglionic blocking drugs, assaultT44.2X4 Poisoning by ganglionic blocking drugs, undeterminedT44.2X5 Adverse effect of ganglionic blocking drugsT44.2X6 Underdosing of ganglionic blocking drugsT44.3 Parasympatholytics and spasmolyticsT44.3X Parasympatholytics and spasmolyticsT44.3X1 Poisoning by oth parasympath and spasmolytics, accidentalT44.3X2 Poisoning by oth parasympath and spasmolytics, self-harmT44.3X3 Poisoning by oth parasympath and spasmolytics, assaultT44.3X4 Poisoning by oth parasympath and spasmolytics, undeterminedT44.3X5 Adverse effect of other parasympatholytics and spasmolyticsT44.3X6 Underdosing of other parasympatholytics and spasmolyticsT44.4 Predominantly alpha-adrenoreceptor agonistsT44.4X Predominantly alpha-adrenoreceptor agonistsT44.4X1 Poisoning by predom alpha-adrenocpt agonists, accidentalT44.4X2 Poisoning by predom alpha-adrenocpt agonists, self-harmT44.4X3 Poisoning by predominantly alpha-adrenocpt agonists, assaultT44.4X4 Poisoning by predom alpha-adrenocpt agonists, undeterminedT44.4X5 Adverse effect of predominantly alpha-adrenocpt agonistsT44.4X6 Underdosing of predominantly alpha-adrenoreceptor agonists

Billable codes in T44

CodeDescription
T44.0X1APoisoning by anticholinesterase agents, accidental (unintentional), initial encounter
T44.0X1DPoisoning by anticholinesterase agents, accidental (unintentional), subsequent encounter
T44.0X1SPoisoning by anticholinesterase agents, accidental (unintentional), sequela
T44.0X2APoisoning by anticholinesterase agents, intentional self-harm, initial encounter
T44.0X2DPoisoning by anticholinesterase agents, intentional self-harm, subsequent encounter
T44.0X2SPoisoning by anticholinesterase agents, intentional self-harm, sequela
T44.0X3APoisoning by anticholinesterase agents, assault, initial encounter
T44.0X3DPoisoning by anticholinesterase agents, assault, subsequent encounter
T44.0X3SPoisoning by anticholinesterase agents, assault, sequela
T44.0X4APoisoning by anticholinesterase agents, undetermined, initial encounter
T44.0X4DPoisoning by anticholinesterase agents, undetermined, subsequent encounter
T44.0X4SPoisoning by anticholinesterase agents, undetermined, sequela
T44.0X5AAdverse effect of anticholinesterase agents, initial encounter
T44.0X5DAdverse effect of anticholinesterase agents, subsequent encounter
T44.0X5SAdverse effect of anticholinesterase agents, sequela
T44.0X6AUnderdosing of anticholinesterase agents, initial encounter
T44.0X6DUnderdosing of anticholinesterase agents, subsequent encounter
T44.0X6SUnderdosing of anticholinesterase agents, sequela
T44.1X1APoisoning by other parasympathomimetics [cholinergics], accidental (unintentional), initial encounter
T44.1X1DPoisoning by other parasympathomimetics [cholinergics], accidental (unintentional), subsequent encounter
T44.1X1SPoisoning by other parasympathomimetics [cholinergics], accidental (unintentional), sequela
T44.1X2APoisoning by other parasympathomimetics [cholinergics], intentional self-harm, initial encounter
T44.1X2DPoisoning by other parasympathomimetics [cholinergics], intentional self-harm, subsequent encounter
T44.1X2SPoisoning by other parasympathomimetics [cholinergics], intentional self-harm, sequela
T44.1X3APoisoning by other parasympathomimetics [cholinergics], assault, initial encounter
T44.1X3DPoisoning by other parasympathomimetics [cholinergics], assault, subsequent encounter
T44.1X3SPoisoning by other parasympathomimetics [cholinergics], assault, sequela
T44.1X4APoisoning by other parasympathomimetics [cholinergics], undetermined, initial encounter
T44.1X4DPoisoning by other parasympathomimetics [cholinergics], undetermined, subsequent encounter
T44.1X4SPoisoning by other parasympathomimetics [cholinergics], undetermined, sequela
T44.1X5AAdverse effect of other parasympathomimetics [cholinergics], initial encounter
T44.1X5DAdverse effect of other parasympathomimetics [cholinergics], subsequent encounter
T44.1X5SAdverse effect of other parasympathomimetics [cholinergics], sequela
T44.1X6AUnderdosing of other parasympathomimetics [cholinergics], initial encounter
T44.1X6DUnderdosing of other parasympathomimetics [cholinergics], subsequent encounter
T44.1X6SUnderdosing of other parasympathomimetics [cholinergics], sequela
T44.2X1APoisoning by ganglionic blocking drugs, accidental (unintentional), initial encounter
T44.2X1DPoisoning by ganglionic blocking drugs, accidental (unintentional), subsequent encounter
T44.2X1SPoisoning by ganglionic blocking drugs, accidental (unintentional), sequela
T44.2X2APoisoning by ganglionic blocking drugs, intentional self-harm, initial encounter
T44.2X2DPoisoning by ganglionic blocking drugs, intentional self-harm, subsequent encounter
T44.2X2SPoisoning by ganglionic blocking drugs, intentional self-harm, sequela
T44.2X3APoisoning by ganglionic blocking drugs, assault, initial encounter
T44.2X3DPoisoning by ganglionic blocking drugs, assault, subsequent encounter
T44.2X3SPoisoning by ganglionic blocking drugs, assault, sequela
T44.2X4APoisoning by ganglionic blocking drugs, undetermined, initial encounter
T44.2X4DPoisoning by ganglionic blocking drugs, undetermined, subsequent encounter
T44.2X4SPoisoning by ganglionic blocking drugs, undetermined, sequela
T44.2X5AAdverse effect of ganglionic blocking drugs, initial encounter
T44.2X5DAdverse effect of ganglionic blocking drugs, subsequent encounter
T44.2X5SAdverse effect of ganglionic blocking drugs, sequela
T44.2X6AUnderdosing of ganglionic blocking drugs, initial encounter
T44.2X6DUnderdosing of ganglionic blocking drugs, subsequent encounter
T44.2X6SUnderdosing of ganglionic blocking drugs, sequela
T44.3X1APoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), initial encounter
T44.3X1DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), subsequent encounter
T44.3X1SPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, accidental (unintentional), sequela
T44.3X2APoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, initial encounter
T44.3X2DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, subsequent encounter
T44.3X2SPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, intentional self-harm, sequela
T44.3X3APoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, initial encounter
T44.3X3DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, subsequent encounter
T44.3X3SPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, assault, sequela
T44.3X4APoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, initial encounter
T44.3X4DPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, subsequent encounter
T44.3X4SPoisoning by other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, undetermined, sequela
T44.3X5AAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X5DAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.3X5SAdverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.3X6AUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter
T44.3X6DUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter
T44.3X6SUnderdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
T44.4X1APoisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), initial encounter
T44.4X1DPoisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
T44.4X1SPoisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional), sequela
T44.4X2APoisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter
T44.4X2DPoisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T44.4X2SPoisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, sequela
T44.4X3APoisoning by predominantly alpha-adrenoreceptor agonists, assault, initial encounter
T44.4X3DPoisoning by predominantly alpha-adrenoreceptor agonists, assault, subsequent encounter
T44.4X3SPoisoning by predominantly alpha-adrenoreceptor agonists, assault, sequela
T44.4X4APoisoning by predominantly alpha-adrenoreceptor agonists, undetermined, initial encounter
T44.4X4DPoisoning by predominantly alpha-adrenoreceptor agonists, undetermined, subsequent encounter
T44.4X4SPoisoning by predominantly alpha-adrenoreceptor agonists, undetermined, sequela
T44.4X5AAdverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X5DAdverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.4X5SAdverse effect of predominantly alpha-adrenoreceptor agonists, sequela
T44.4X6AUnderdosing of predominantly alpha-adrenoreceptor agonists, initial encounter
T44.4X6DUnderdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter
T44.4X6SUnderdosing of predominantly alpha-adrenoreceptor agonists, sequela
T44.5X1APoisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), initial encounter
T44.5X1DPoisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), subsequent encounter
T44.5X1SPoisoning by predominantly beta-adrenoreceptor agonists, accidental (unintentional), sequela
T44.5X2APoisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter
T44.5X2DPoisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, subsequent encounter
T44.5X2SPoisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, sequela
T44.5X3APoisoning by predominantly beta-adrenoreceptor agonists, assault, initial encounter
T44.5X3DPoisoning by predominantly beta-adrenoreceptor agonists, assault, subsequent encounter
T44.5X3SPoisoning by predominantly beta-adrenoreceptor agonists, assault, sequela
T44.5X4APoisoning by predominantly beta-adrenoreceptor agonists, undetermined, initial encounter
T44.5X4DPoisoning by predominantly beta-adrenoreceptor agonists, undetermined, subsequent encounter
T44.5X4SPoisoning by predominantly beta-adrenoreceptor agonists, undetermined, sequela
T44.5X5AAdverse effect of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X5DAdverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter
T44.5X5SAdverse effect of predominantly beta-adrenoreceptor agonists, sequela
T44.5X6AUnderdosing of predominantly beta-adrenoreceptor agonists, initial encounter
T44.5X6DUnderdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter
T44.5X6SUnderdosing of predominantly beta-adrenoreceptor agonists, sequela
T44.6X1APoisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), initial encounter
T44.6X1DPoisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
T44.6X1SPoisoning by alpha-adrenoreceptor antagonists, accidental (unintentional), sequela
T44.6X2APoisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter
T44.6X2DPoisoning by alpha-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T44.6X2SPoisoning by alpha-adrenoreceptor antagonists, intentional self-harm, sequela
T44.6X3APoisoning by alpha-adrenoreceptor antagonists, assault, initial encounter
T44.6X3DPoisoning by alpha-adrenoreceptor antagonists, assault, subsequent encounter
T44.6X3SPoisoning by alpha-adrenoreceptor antagonists, assault, sequela
T44.6X4APoisoning by alpha-adrenoreceptor antagonists, undetermined, initial encounter
T44.6X4DPoisoning by alpha-adrenoreceptor antagonists, undetermined, subsequent encounter
T44.6X4SPoisoning by alpha-adrenoreceptor antagonists, undetermined, sequela
T44.6X5AAdverse effect of alpha-adrenoreceptor antagonists, initial encounter
T44.6X5DAdverse effect of alpha-adrenoreceptor antagonists, subsequent encounter
T44.6X5SAdverse effect of alpha-adrenoreceptor antagonists, sequela
T44.6X6AUnderdosing of alpha-adrenoreceptor antagonists, initial encounter
T44.6X6DUnderdosing of alpha-adrenoreceptor antagonists, subsequent encounter
T44.6X6SUnderdosing of alpha-adrenoreceptor antagonists, sequela
T44.7X1APoisoning by beta-adrenoreceptor antagonists, accidental (unintentional), initial encounter
T44.7X1DPoisoning by beta-adrenoreceptor antagonists, accidental (unintentional), subsequent encounter
T44.7X1SPoisoning by beta-adrenoreceptor antagonists, accidental (unintentional), sequela
T44.7X2APoisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter
T44.7X2DPoisoning by beta-adrenoreceptor antagonists, intentional self-harm, subsequent encounter
T44.7X2SPoisoning by beta-adrenoreceptor antagonists, intentional self-harm, sequela
T44.7X3APoisoning by beta-adrenoreceptor antagonists, assault, initial encounter
T44.7X3DPoisoning by beta-adrenoreceptor antagonists, assault, subsequent encounter
T44.7X3SPoisoning by beta-adrenoreceptor antagonists, assault, sequela
T44.7X4APoisoning by beta-adrenoreceptor antagonists, undetermined, initial encounter
T44.7X4DPoisoning by beta-adrenoreceptor antagonists, undetermined, subsequent encounter
T44.7X4SPoisoning by beta-adrenoreceptor antagonists, undetermined, sequela
T44.7X5AAdverse effect of beta-adrenoreceptor antagonists, initial encounter
T44.7X5DAdverse effect of beta-adrenoreceptor antagonists, subsequent encounter
T44.7X5SAdverse effect of beta-adrenoreceptor antagonists, sequela
T44.7X6AUnderdosing of beta-adrenoreceptor antagonists, initial encounter
T44.7X6DUnderdosing of beta-adrenoreceptor antagonists, subsequent encounter
T44.7X6SUnderdosing of beta-adrenoreceptor antagonists, sequela
T44.8X1APoisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), initial encounter
T44.8X1DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), subsequent encounter
T44.8X1SPoisoning by centrally-acting and adrenergic-neuron-blocking agents, accidental (unintentional), sequela
T44.8X2APoisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter
T44.8X2DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, subsequent encounter
T44.8X2SPoisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, sequela
T44.8X3APoisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, initial encounter
T44.8X3DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, subsequent encounter
T44.8X3SPoisoning by centrally-acting and adrenergic-neuron-blocking agents, assault, sequela
T44.8X4APoisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, initial encounter
T44.8X4DPoisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, subsequent encounter
T44.8X4SPoisoning by centrally-acting and adrenergic-neuron-blocking agents, undetermined, sequela
T44.8X5AAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X5DAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T44.8X5SAdverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.8X6AUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter
T44.8X6DUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter
T44.8X6SUnderdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela
T44.901APoisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), initial encounter
T44.901DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
T44.901SPoisoning by unspecified drugs primarily affecting the autonomic nervous system, accidental (unintentional), sequela
T44.902APoisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
T44.902DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
T44.902SPoisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, sequela
T44.903APoisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, initial encounter
T44.903DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, subsequent encounter
T44.903SPoisoning by unspecified drugs primarily affecting the autonomic nervous system, assault, sequela
T44.904APoisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, initial encounter
T44.904DPoisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, subsequent encounter
T44.904SPoisoning by unspecified drugs primarily affecting the autonomic nervous system, undetermined, sequela
T44.905AAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.905DAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44.905SAdverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.906AUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter
T44.906DUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter
T44.906SUnderdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela
T44.991APoisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), initial encounter
T44.991DPoisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), subsequent encounter
T44.991SPoisoning by other drug primarily affecting the autonomic nervous system, accidental (unintentional), sequela
T44.992APoisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
T44.992DPoisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, subsequent encounter
T44.992SPoisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, sequela
T44.993APoisoning by other drug primarily affecting the autonomic nervous system, assault, initial encounter
T44.993DPoisoning by other drug primarily affecting the autonomic nervous system, assault, subsequent encounter
T44.993SPoisoning by other drug primarily affecting the autonomic nervous system, assault, sequela
T44.994APoisoning by other drug primarily affecting the autonomic nervous system, undetermined, initial encounter
T44.994DPoisoning by other drug primarily affecting the autonomic nervous system, undetermined, subsequent encounter
T44.994SPoisoning by other drug primarily affecting the autonomic nervous system, undetermined, sequela
T44.995AAdverse effect of other drug primarily affecting the autonomic nervous system, initial encounter
T44.995DAdverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44.995SAdverse effect of other drug primarily affecting the autonomic nervous system, sequela
T44.996AUnderdosing of other drug primarily affecting the autonomic nervous system, initial encounter
T44.996DUnderdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter
T44.996SUnderdosing of other drug primarily affecting the autonomic nervous system, sequela

Search within ICD-10-CM for T44 and related codes

Advertisement